Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector

cansino biologics inc./beijing institute of biotechnology

cansino biologics inc./beijing institute of biotechnology - win

An encapsulation of CanSino’s adenovirus type-5 vectored COVID-19 vaccine

An encapsulation of CanSino’s adenovirus type-5 vectored COVID-19 vaccine

https://preview.redd.it/nvkic6yeay461.jpg?width=4000&format=pjpg&auto=webp&s=d1579f910e5e35228c986c956438a4c6dadd554b
On September 22, 2020 the National Command and Operation Centre (NCOC). Announced the launch of phase 3 clinical trials in Pakistan for a potential vaccine being developed by China’s CanSino Biologics Inc. | Beijing Institute of Biotechnology for the novel coronavirus. Ad5-nCoV is a viral vector vaccine that has successfully passed the phase 1 and 2 clinical trials and now its success in phase 3 clinical trials is imminent. Ad5-nCoV is one of the most advanced candidates in vaccine development worldwide. It is a viral vector vaccine. A viral vector vaccine comprises of virus as a non-harmful virus as vector to which segment of viral gene against which vaccine is to be created is attached using recombinant DNA technology. This recombinant structure is when incorporated in a host it trigger an immune response. These vaccines are highly specific in delivering the genes to the target cells, highly efficient in the gene transduction, and efficiently induce the immune response. They offer a long term and high level of antigenic protein expression and therefore, have a great potential for prophylactic use as these vaccines trigger and prime the cytotoxic T cells (CTL) which ultimately leads to the elimination of the virus infected cells. Adenovirus vector vaccines of various sorts have gone into human trials for HIV, influenza, Ebola, tuberculosis, and malaria.
In case of Ad5-nCoV, adenovirus type 5 is used as a viral vector that expresses the spike glycoprotein of SARS COV-2. For the development of SARS COV-2 vaccine the viral gene was cloned and constructed into adenovirus type 5 viral vector with E1 and E3 deletion using the Admax system. This vaccine was created as a liquid formulation that is allocated intramuscularly in the arms of the patient. During phase 1 and 2 when vaccine was injected following results were collected
· Ad5-nCoV vaccine was tolerable in all group of adults and the only adverse effects collected were tolerable headache, mild fever and fatigue.
· Ad5 vectored COVID-19 vaccine was immunogenic, inducing humoral and T-cell responses rapidly in most participants.
· There was a four-fold increase in the RBD and S protein-specific neutralizing antibodies within 14 days of immunization and it peaked at day 28 of post-vaccination.
· The preexisting anti Ad5 antibodies limited the response of immune response.

Bibliography


Feng-Cai Zhu*, Y.-H. L.-H.-H.-J.-X.-P.-S.-Y. (2020). Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine:. Lancet 2020, 10.
submitted by khyzer09 to The_Science_Cult [link] [comments]

Whats in a Vaccine?

a few links to read

GAVI, an organization that provides vaccines to underserved populations, says that at least 60% of the world’s population will need to be vaccinated to achieve herd immunity and begin stamping out COVID-19. “You can’t go back to your normal trade, travel or movement of people” unless everyone gets vaccinated, GAVI CEO Seth Berkley recently told the BBC. “It’s really important to have that mindset: we’re not safe, unless everybody is safe.”
https://fortune.com/2020/08/22/china-covid-vaccine-sinopharm-price-cost/

________________________________________________________
GAVI & WELLCOME are GATES

BBC - 13th Aug - Coronavirus: How will the world vaccinate seven billion?
Seth Berkley, Gavi's CEO, says one of the biggest hurdles he's facing is so-called "vaccine nationalism".
"I think we need all countries to be thinking about this in a globally minded way, partially because it's the right thing to do but also because it's a self-interest issue," he says.
"If you have large reservoirs of virus circulating in surrounding countries, you can't go back to your normal trade, travel or movement of people. It's really important to have that mindset: we're not safe, unless everybody is safe."
Dr Charlie Weller, head of vaccines at the UK's Wellcome Trust, says countries are going to have to ask some frank questions.
"Who needs this vaccine? Which are the highest risk groups? And who are the highest priority? Because what we're pretty clear about is any initial vaccine is likely to outstrip supply, so choices will need to be made."
https://www.bbc.com/news/health-53741966

________________________________________________________

Chinese mining company used COVID-19 vaccine on employees in Papa New Guinea: Report
A document on company letterhead entitled "Vaccination Statement" said 48 Chinese employees "have been vaccinated with SARS-COV-2 vaccine" on August 10.
Published: 21st August 2020 12:11 PM
CANBERRA: A Chinese mining company in Papua New Guinea claims to have immunised employees against COVID-19 in an apparent vaccination trial, a newspaper reported on Friday.
The South Pacific island nation's Health Minister Papua Jelta Wong said his department was investigating the claim by Ramu NiCo Management (MCC) Ltd., The Australian reported.
National Pandemic Response Controller David Manning banned COVID-19 vaccine testing or trials in Papua New Guinea on Thursday and later noted the National Department of Health had not approved any trials.
"Any vaccines imported into PNG must be approved by NDoH and must go through vigorous vaccine trials, protocols and procedures" and must be pre-qualified by the World Health Organization, Manning said in a statement on Friday.
Wong did not immediately respond to a request for comment on Friday.

A document on company letterhead entitled "Vaccination Statement" said 48 Chinese employees "have been vaccinated with SARS-COV-2 vaccine" on August 10.
The statement was sent to the Papua New Guinea Health Department and advised that the vaccine could cause false-positive test results in those who received it, the newspaper said.
Manning has written to Chinese Ambassador Xue Bing seeking "immediate clarification of the Chinese government's position regarding the vaccination statement."
Ramu is operated by Metallurgical Corp.of China, a subsidiary of state-owned China Metallurgical Group Corp.
Phone calls to Ramu's office in the Papua New Guinea city of Madang and to the parent company's Beijing headquarters in Beijing weren't answered.
Australia, which is Papua New Guinea's nearest neighbor after Indonesia and its largest provider of foreign aid, had learned China may have begun trialing a coronavirus vaccine in the region using employees of state-owned enterprises, the newspaper reported.
Australian government officials did not immediately respond to requests for comment on Friday.
Papua New Guinea is a poor country of 9 million people who are mostly subsistence farmers.
It has recorded only 361 COVID-19 cases and four deaths.
But infections have surged in the past month, particularly in the capital Port Moresby where a curfew is being enforced as a pandemic measure.
https://www.newindianexpress.com/world/2020/aug/21/chinese-mining-company-used-covid-19-vaccine-on-employees-in-papa-new-guinea-report-2186473.html
________________________________________________________

It was unclear which Chinese producer supplied the vaccine.

State-owned China National Pharmaceutical Group Co., Ltd., also known as SinoPharm, announced in July it gave experimental shots of a vaccine to its employees before the government approved testing in people.
In Indonesia, another Chinese company, Sinovac Biotech Ltd., began testing a vaccine this month on 1,620 volunteers in partnership with state-owned Bio Farma.
https://thediplomat.com/2020/08/papua-new-guinea-demands-china-explain-covid-19-vaccine-trial-on-miners/
________________________________________________________

Vials of a COVID-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China March 24, 2020.
https://www.cbsnews.com/news/covid-vaccine-chinese-mine-workers-papua-new-guinea/
________________________________________________________

The mining company
As a super conglomerate, China Metallurgical Group Corporation (MCC Group) is the longest-running construction force in China’s iron and steel industry, serving as the pioneer and main force in this field.
http://www.mcc.com.cn/mccen/about_mcc/about_mcc60/index.html

________________________________________________________

whats in the vaccine?

nanomaterial?

Vaccination, one of the most effective strategies to prevent infectious diseases, is the administration of antigenic materials to stimulate an individual’s immune system to develop adaptive immunity to a specific pathogen. Though it is so advantageous for diseases control and prevention, vaccines still have some limitations. Nanotechnology is an approach to prepare a novel biomedicine vaccine with the vaccine consumption and side effects significantly decreased. Regulation is the most important criterion for the development of nanovaccines. All marketing products have to meet the requirement of regulation. The fast-track designation potentially aids in the development and expedites the review of nanovaccines that show promises in an unmet medical need. Here, some successful nanovaccine products are introduced—Inflexal® V, Epaxal®, GardasilTM, and CervarixTM have been widely used for the clinical applications, which are delivered either in the form of virosomes or virus-like particles. Vaccines based on nanotechnology may overcome their original disadvantages and lead to the development of painless, safer, and more effective products.

https://www.intechopen.com/books/micro-and-nanotechnologies-for-biotechnology/nanotechnologies-applied-in-biomedical-vaccines

________________________________________________________

Nanoparticle/nanocarrier: The live-attenuated and inactivated viral vaccines can be regarded as nanoparticles themselves. Rather than serving as the vaccine itself, a nanoparticle (viral or non-viral) can be employed as nanocarrier to encapsulate or present the antigen payload or nucleic acid encoding the antigen. Nanocarriers provide stability and targeting of these payloads to antigen presenting cells (APCs); nanocarriers can confer innate adjuvant behaviour (see Fig. 3). Nanocarriers synchronize delivery of both, antigen and adjuvant, to target immune cells.• Viral vector: repurposed mammalian viruses engineered to deliver a gene encoding the antigen (examples include adeno-viral vectors derived from chimpanzee and human).• Proteinaceous nanoparticles: nanoscale biomaterial assem-blies with atomic precision and complexity (examples include protein nanocages and non-infectious viruses such as plant viruses or bacteriophages) engineered to present a subunit vaccine or deliver a nucleic acid encoding the antigen.• Synthetic nanoparticles: nanoscale assemblies of synthetic materials (examples include polymer, liposomal, or lipid nano-particles) engineered to present a subunit vaccine or deliver a nucleic acid encoding the antigen

https://www.nature.com/articles/s41565-020-0737-y.pdf

________________________________________________________


In the next 10 or so years, your blood will probably be streaming with tiny nanorobots there to help keep you from getting sick or even transmit your thoughts to a wireless cloud. They will travel inside of you, on a molecular level, protecting the biological system and ensuring that you have a good and long life. The future is closer than you may think.

https://interestingengineering.com/nanobots-will-flowing-body-2030

________________________________________________________

This work presents a new approach with details on the integrated platform and hardware architecture for nanorobots application in epidemic control, which should enable real time in vivo prognosis of biohazard infection.
The recent developments in the field of nanoelectronics, with transducers progressively shrinking down to smaller sizes through nanotechnology and carbon nanotubes, are expected to result in innovative biomedical instrumentation possibilities, with new therapies and efficient diagnosis methodologies.
The use of integrated systems, smart biosensors, and programmable nanodevices are advancing nanoelectronics, enabling the progressive research and development of molecular machines. It should provide high precision pervasive biomedical monitoring with real time data transmission.
The use of nanobioelectronics as embedded systems is the natural pathway towards manufacturing methodology to achieve nanorobot applications out of laboratories sooner as possible.
To demonstrate the practical application of medical nanorobotics, a 3D simulation based on clinical data addresses how to integrate communication with nanorobots using RFID, mobile phones, and satellites, applied to long distance ubiquitous surveillance and health monitoring for troops in conflict zones. Therefore, the current model can also be used to prevent and save a population against the case of some targeted epidemic disease.
[snip]
The proposed model uses electromagnetic radio waves to command and detect the current status of nanorobots inside the body. Therefore, the cell phone is applied for medical nanorobotics platform [7,64,65]. This occurs as the cell phone emits a magnetic signature to the passive CMOS sensors embedded in the nanorobot, which enables sending and receiving data through electromagnetic fields [66]. From the last set of events recorded in pattern arrays, information can be reflected back by wave resonance [64].
The nanorobot model includes embedded IC (integrated circuit) nanoelectronics [67], and the architecture involves the use of satellites and mobile phones for data transmission and coupling energy [68,69]. The nanorobot is programmed for sensing and to detect concentration of alpha-NAGA in the bloodstream [7,16,70]. The nanorobot architecture uses an RFID (radio frequency identification device) CMOS transponder system for in vivo positioning [70], adopting well established communication protocols, which allow track information about the nanorobot position [5,7].
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675524/

________________________________________________________
A team has proposed using nanobots to create the ‘internet of thoughts’, where instant knowledge could be downloaded just by thinking it.
An international team of scientists led by members of UC Berkeley and the US Institute for Molecular Manufacturing predicts that exponential progress in nanotechnology, nanomedicine, artificial intelligence (AI) and computation will lead this century to the development of a human ‘brain-cloud interface’ (B-CI).

https://www.siliconrepublic.com/machines/brain-cloud-interface-nanobots-global-superbrain

________________________________________________________

Facebook has assembled a team of 60 engineers working on artificial intelligence and neural prosthetics to create a system that can read your brainwaves and translate them, 100 words per minute.
https://www.siliconrepublic.com/machines/facebook-talk-with-your-brain

so - did the Chinese just put a nano rfid into some miners in the form of a Vaccine
what will be in the vaccines they are developing?
submitted by w4rdr0b3 to conspiracy [link] [comments]

Coronavirus Vaccines Pipeline Analysis with Key Features & Trends

Coronavirus Vaccines Pipeline Analysis with Key Features & Trends
Coronavirus Vaccines Pipeline Analysis

The latest research report published by DPI Research entitled “Coronavirus Vaccines Pipeline Analysis” provides a complete view of the current proceedings within the market. The report delivers crucial data in the form of tables, charts, graphs and figures in a comprehensive study of the Coronavirus Vaccines Pipeline Analysis.
Download Free Sample Report @ https://dpiresearch.com/request-a-free-sample-report/
“Coronavirus (COVID 19) Vaccine Pipeline Assessment 2020” provides a comprehensive analysis of the fast-evolving, high-growth global Coronavirus (COVID 19) vaccine market. The report offers the most up-to-date industry data on the actual market situation for the Coronavirus (COVID 19) vaccine.
The report explores a detailed analysis of the introduction of the coronavirus, pathogen characteristics, signs and symptoms, transmission, and prevention. It also evaluates the vaccines developed against MERS-CoV and SARS-CoV. The report reviews a clear insight into the funding of the Coronavirus (COVID-19) vaccine research. The report also offers comprehensive information about the recruiting clinical trials statement by phase, trial status, study sponsor name, and study phase. The report investigates detailed insights about countries, territories, or areas with reported laboratory-confirmed Coronavirus (COVID-19) cases and deaths. Key trends in terms of collaboration and partnership deals are analyzed with details.
The report concludes with the profiles of the key vaccine developers in the global coronavirus vaccine market. The key players are evaluated on the various parameters such as business overview, promising vaccine in clinical development, and recent development.
Report Scope:
  • Extensive coverage of the Coronavirus (COVID-19) vaccine under development
  • Detailed Insights of the Introduction, Pathogen Characteristics, Signs and Symptoms, Transmission and Prevention
  • Provides Comprehensive Insights on the Funding of the Coronavirus (COVID-19) Vaccine Research
  • Thoroughly Evaluates Vaccines Developed Against MERS-CoV and SARS-CoV
  • Reviews Most Recent Clinical Trials of the Coronavirus Vaccines
  • Scrutinizes Countries, Territories or Areas with Reported Laboratory-Confirmed Coronavirus (COVID-19) Cases and Deaths
  • Provides Key Trends with Respect to Collaboration and Partnership Deals
  • An Insightful Analysis of the Key Vaccine Developers Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development
Enquire for customization in Report @: https://dpiresearch.com/services/custom-research-services-providing-focused-comprehensive-tailored-research/
Key Vaccine Developers Covered in the Report
  • University of Oxford
  • Clover Biopharmaceuticals/Dynavax/GlaxoSmithKline
  • Heat Biologics Inc./University of Miami
  • Inovio Pharmaceuticals Inc
  • Janssen Pharmaceutical
  • Sanofi PasteuGlaxoSmithKline (GSK)
  • Moderna/NIAID
  • Novavax
  • Sanofi PasteuTranslate Bio Inc.
  • Vaxart Inc.
  • Altimmune
  • Medicago
  • BioNTech/PfizeFosun Pharma
  • GeoVax/BravoVax
  • Arcturus Therapeutics/Duke-NUS
  • CanSino Biological Inc/Beijing Institute of Biotechnology
  • Takis Biotech/Applied DNA Sciences/Evvivax
  • Cobra Biologics/Karolinska Institute
  • Zydus Cadila
  • Codagenix/Serum Institute of India
  • Greffex
  • ExpreS2ion Biotechnologies ApS
  • Vaxil Bio Therapeutics
  • Flow Pharma Inc
  • AJ Vaccines
  • Generex Biotechnology/EpiVax
  • Immunomic Therapeutics/EpiVax/PharmaJet
  • iBio Inc/CC-Pharming Ltd/Infectious Disease Research Institute
  • VIDO-InterVac/University of Saskatchewan/International Vaccine Institute
  • Tonix Pharmaceuticals/Southern Research
  • IAVI/Batavia Biosciences
  • Curevac
  • Imophoron Ltd/University of Bristol
  • BioNet Asia
  • Sinovac/Dynavax
  • BIOCAD
  • University of Pittsburgh
For More Information@ https://dpiresearch.com/reports/coronavirus-covid-19-vaccine/
The report is readily available and can be dispatched immediately after payment confirmation.
Would like to place an order or any question, please feel free to contact at [email protected]
Customization of the Report:
DPI Research provides customization of the report as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.
Contact Us: Maria Rai Head of Business Development DPI Research | Web: https://dpiresearch.com Direct Line: +91-766-764-8693 E-mail: [email protected]
About Us:
DPI Research is a leading market research publisher which offer bespoke market research reports, custom research and consulting services across multi geographies and industry verticals. We deliver a wide range of cutting-edge research solutions that help organizations in making better decisions of the business to business needs.
DPI Research provides a high standard of business research reports to the clients across industry verticals comprising Life Sciences, Information Technology, Telecom & Internet, Food Beverages & Agriculture, Travel & Tourism, Consumer Goods & Retail, Education and Social Sciences. We are committed to using advanced analytical tools and methodologies to help clients with crucial industry information for decision making.
DPI Research approaches for business research led by a team of dynamic industry experts. DPI Research provides real insight for effective decisions to help business with the help of current source and accurate data available in the market. DPI Research reaches across the globe with global standards from established markets in North America and Europe to emerging markets in South America, Asia-Pacific, Middle East, and Africa to provide the best business solutions.
submitted by mariarai1 to u/mariarai1 [link] [comments]

cansino biologics inc./beijing institute of biotechnology video

- CanSino Biologics, Inc. Beijing Institute of Biotechnology, CanSino Biologics/Beijing Institute of Biotechnology, et Inovio Pharmaceuticals font ainsi usage d'une lignée de cellules de rein de foetus dénommée HEK-293, issue d'un foetus avorté en 1972 aux Pays-Bas. Quant à la firme Janss... Lire la suite . Controverses autour de la vaccination contre le cancer du col de l’utérus A coronavirus vaccine tested for the first time in humans is safe and induces a rapid immune response, researchers at China's CanSino Biologics Inc reported on Friday in The Lancet medical journal. TIANJIN, CHINA, January 2, 2020, CanSino Biologics Inc. (“CanSinoBIO” or the “Company”, 6185.HK) announced the appointment of Dr. Pierre Armand Morgon as Senior Vice President responsible for international business operation. The appointment indicated a further step forward in the Company’s commitment to global development and growth. China-based CanSino Biologics has received regulatory approval to conduct Phase I clinical trial of recombinant novel coronavirus vaccine (adenovirus type 5 vector) candidate. The candidate is being developed in alliance with Beijing Institute of Biotechnology (BIB), based on the viral vector vaccine technology platform previously used to develop Ebola vaccine. This is a global phase III clinical trial to evaluate efficacy,safety, immuogenicity of Ad5-nCoV manufactured by Cansino and Beijing Institute of Biotechnology in health adults aged 18 years old and above. The study will be double-blind, placebo-controlled trial with participants randomly allocated 1:1 to placebo and experimental vaccine cohorts. Beijing approves CanSino Biologics's experimental Covid-19 vaccine for use in Chinese military By Ben Westcott, CNN 6/30/2020 Honor for fallen officer, impeachment trial, Groundhog Day: 5 things march 17 (reuters) - cansino biologics inc: * co & institute of biotechnology, academy of military medical sciences jointly developing recombinant novel coronavirus vaccine Last week, the Hong-Kong listed CanSino Biological said that it’s taking its vaccine candidate for Ebola into phase 2 trials after preliminary safety data showed efficacy against Covid-19. CanSino will develop the vaccine along with the Beijing Institute of Biotechnology and the Academy of Military Medical Sciences. CanSino Biological/Beijing Institute of Biotechnology CanSino Biologics, Inc. Beijing Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China (Chine) Gamaleya Research Institute (Russie) Janssen Research & Development, Inc. Johnson & Johnson (Etats-Unis) Vaxart (Etats-Unis) Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences (Chine) University of Pittsburgh (Etats-Unis) 2. Phase de Academy of Military Medical Sciences’ Institute of Biotechnology Ad5-nCoV CanSino Biologics Coronavirus COVID-19 Vaccine 0 China’s CanSino Biologics recently disclosed that the company was advancing its SARS-CoV-2 vaccine to a Phase II clinical trial making this vaccine candidate lead contender in the global race for an approved vaccine product.

cansino biologics inc./beijing institute of biotechnology top

[index] [1416] [4115] [1514] [877] [1187] [4974] [4453] [2718] [8845] [7080]

cansino biologics inc./beijing institute of biotechnology

Copyright © 2024 m.trysport.site